What Breast Cancer Is and Typical Symptoms
Breast cancer occurs when cells within breast tissue mutate and divide uncontrollably. It most frequently develops in the milk ducts (invasive ductal carcinoma, accounting for 70 to 80 percent of cases) or in the milk-producing lobules (invasive lobular carcinoma). While primarily diagnosed in women, men also have breast tissue and can develop the disease. Clinical behaviour and treatment response depend on receptor status, specifically whether tumour cells express oestrogen receptors (ER), progesterone receptors (PR), or human epidermal growth factor receptor 2 (HER2), alongside the Ki-67 proliferation rate.
Early-stage breast cancer frequently causes no pain or obvious discomfort. When symptoms do emerge, they may include:
- A firm, non-tender lump or distinct area of thickening in the breast or armpit.
- Changes in the size, shape, or bilateral symmetry of the breast.
- Skin changes, such as dimpling, puckering, redness, or an orange-peel texture.
- Nipple alterations, including sudden inversion, scaling, or unexplained spontaneous discharge.
- Persistent focal breast or underarm discomfort unrelated to normal menstrual cycles.
Because benign conditions such as cysts or fibroadenomas often cause similar changes, timely assessment through specialised Check-ups & Diagnostics is essential to establish an accurate diagnosis.
How Breast Cancer Is Diagnosed
Accurate staging and molecular characterisation guide every treatment decision. Accredited hospitals in Turkey employ standardised diagnostic pathways to evaluate disease extent:
- Diagnostic imaging: Bilateral digital mammography and ultrasound assess suspicious lesions. Breast MRI is used for dense tissue, occult tumours, or multifocal disease.
- Core needle biopsy: A guided needle biopsy obtains tissue samples for histological grading and immunohistochemistry to determine ER, PR, HER2, and Ki-67 status.
- Sentinel lymph node staging: Axillary ultrasound and intraoperative sentinel lymph node biopsy evaluate whether cancer cells have entered the underarm lymphatic drainage system.
- Systemic staging: Whole-body PET-CT, chest-abdomen CT, or bone scans determine whether malignant cells have spread to regional lymph nodes or distant organs.
- Genetic testing: Testing for BRCA1, BRCA2, and related gene mutations helps guide surgical choices and long-term risk management.
When travelling, bring original pathology glass slides or paraffin blocks, recent DICOM imaging discs, biopsy reports, and medical summaries. Turkish hospital pathologists routinely re-examine imported tissue samples to confirm receptor status before therapy begins.
Treatment Options and When Each Is Used
Breast cancer care requires a coordinated multidisciplinary approach within Oncology, where surgeons, medical oncologists, radiation specialists, and pathologists collaborate in a tumour board.
| Option |
Typically used when |
Things to know |
| Breast-Conserving Surgery |
Early-stage unifocal tumours with clean margins. |
Performed within General Surgery; usually followed by radiotherapy to minimise local recurrence. |
| Mastectomy & Reconstruction |
Multifocal disease, large tumours, or genetic risk. |
Complete tissue removal; reconstruction coordinates with Plastic & Aesthetic Surgery. |
| Chemotherapy |
Aggressive subtypes (triple-negative, HER2+) or nodal spread. |
Given intravenously over scheduled cycles; requires blood monitoring for marrow suppression. |
| Targeted & Endocrine Therapy |
HER2-positive or hormone-receptor-positive tumours. |
Targeted antibodies accompany chemotherapy; endocrine tablets are taken daily for five to ten years. |
| Radiation Therapy |
Post-lumpectomy or after mastectomy for advanced tumours. |
External beam therapy delivered over several weeks to eradicate microscopic residual cells. |
Supportive care, including manual lymphatic drainage under Rehabilitation specialists, helps manage arm lymphoedema, while consultations in Gynaecology address fertility preservation for younger patients before systemic treatment.
Planning Treatment in Turkey
Travelling for oncological care requires structured planning. Turkish specialists review your diagnostic records remotely to propose provisional options, but definitive recommendations are confirmed only after in-person clinical examination and pathology re-evaluation.
Expected duration of stay varies according to your clinical pathway:
- Diagnostic evaluation: Requires 5 to 7 days for imaging, tissue re-evaluation, and tumour board review.
- Surgical care: Lumpectomy requires 10 to 14 days; mastectomy with reconstruction typically requires 2 to 3 weeks for drain management and wound healing.
- Systemic therapy: Chemotherapy or radiotherapy spans multiple weeks. Many international patients complete surgery abroad and continue maintenance cycles at home.
Before returning home, obtain complete discharge documents including operative notes, pathology reports, and systemic drug schedules. Discuss deep vein thrombosis precautions for your flight, such as compression stockings, and ensure your physician at home agrees to supervise routine blood tests and ongoing surveillance.
When Travel Is Not Advisable
Certain acute complications pose serious risks during long-distance travel. You should not travel if you experience:
- Sudden severe breathlessness, chest pain, or coughing up blood, suggesting pulmonary embolism or pleural effusion.
- Neurological symptoms, severe spinal pain, or loss of bladder control indicating spinal cord compression.
- Neutropenic fever (temperature above 38°C with low white blood cells) or active systemic infection.
- Recent surgery with unhealed wounds, active bleeding, or wound breakdown.
- Uncontrolled brain metastases causing severe headache, vomiting, or altered consciousness.
If acute symptoms arise, seek emergency medical care locally without delay. Travel decisions must always be cleared by your treating doctor after reviewing tests.
